Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609.
Tarhini AA, Lee SJ, Hodi FS, Rao UNM, Cohen GI, Hamid O, Hutchins LF, Sosman JA, Kluger HM, Eroglu Z, Koon HB, Lawrence DP, Kendra KL, Minor DR, Lee CB, Albertini MR, Flaherty LE, Petrella TM, Streicher H, Sondak VK, Kirkwood JM.
Tarhini AA, et al. Among authors: sosman ja.
J Clin Oncol. 2020 Feb 20;38(6):567-575. doi: 10.1200/JCO.19.01381. Epub 2019 Dec 27.
J Clin Oncol. 2020.
PMID: 31880964
Free PMC article.
Clinical Trial.